Skip to main content
GeneralHomeInvestorsNewsUzedy

MedinCell’s partner Teva confirms expectation for approval and commercialization in the US in H1 2023 for mdc-IRM/TEV46000

By July 27, 2022March 15th, 2024No Comments1 min read